WO2003064378A3 - Verbindungen, die faktor xa-aktivität - Google Patents

Verbindungen, die faktor xa-aktivität Download PDF

Info

Publication number
WO2003064378A3
WO2003064378A3 PCT/EP2003/001012 EP0301012W WO03064378A3 WO 2003064378 A3 WO2003064378 A3 WO 2003064378A3 EP 0301012 W EP0301012 W EP 0301012W WO 03064378 A3 WO03064378 A3 WO 03064378A3
Authority
WO
WIPO (PCT)
Prior art keywords
activity
novel compounds
inhibit factor
pharmaceutically acceptable
compounds
Prior art date
Application number
PCT/EP2003/001012
Other languages
English (en)
French (fr)
Other versions
WO2003064378A2 (de
Inventor
Robert Eckl
Silke Schabbert
Thilo Fuchs
Original Assignee
Morphochem Ag Komb Chemie
Robert Eckl
Silke Schabbert
Thilo Fuchs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphochem Ag Komb Chemie, Robert Eckl, Silke Schabbert, Thilo Fuchs filed Critical Morphochem Ag Komb Chemie
Priority to JP2003564002A priority Critical patent/JP2005516062A/ja
Priority to EP03702590A priority patent/EP1470104A2/de
Priority to US10/501,931 priority patent/US20060058389A1/en
Priority to CA002473164A priority patent/CA2473164A1/en
Publication of WO2003064378A2 publication Critical patent/WO2003064378A2/de
Publication of WO2003064378A3 publication Critical patent/WO2003064378A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Die vorliegende Erfindung betrifft Verbindungen der Formel (I), oder ein pharmazeutisch akzeptables Salz, Solvat, Hydrat oder eine pharmazeutisch akzeptable Formulierung derselben. Diese Verbindungen können zur Hemmung von Faktor Xa und zur Vorbeugung und/oder Behandlung von thrombolytischen Erkrankungen verwendet werden.
PCT/EP2003/001012 2002-01-31 2003-01-31 Verbindungen, die faktor xa-aktivität WO2003064378A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003564002A JP2005516062A (ja) 2002-01-31 2003-01-31 Ｘａ因子活性を阻害する新規化合物
EP03702590A EP1470104A2 (de) 2002-01-31 2003-01-31 Verbindungen, die faktor xa-aktivität inhibieren
US10/501,931 US20060058389A1 (en) 2002-01-31 2003-01-31 Novel compounds that inhibit factor xa activity
CA002473164A CA2473164A1 (en) 2002-01-31 2003-01-31 Novel compounds that inhibit factor xa activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10204072A DE10204072A1 (de) 2002-01-31 2002-01-31 Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
DE10204072.9 2002-01-31

Publications (2)

Publication Number Publication Date
WO2003064378A2 WO2003064378A2 (de) 2003-08-07
WO2003064378A3 true WO2003064378A3 (de) 2004-01-08

Family

ID=27588236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001012 WO2003064378A2 (de) 2002-01-31 2003-01-31 Verbindungen, die faktor xa-aktivität

Country Status (7)

Country Link
US (1) US20060058389A1 (de)
EP (1) EP1470104A2 (de)
JP (1) JP2005516062A (de)
CA (1) CA2473164A1 (de)
DE (1) DE10204072A1 (de)
WO (1) WO2003064378A2 (de)
ZA (1) ZA200405544B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556914A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
DE102004034913A1 (de) * 2004-07-19 2006-02-16 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
WO2010018435A1 (en) * 2008-08-11 2010-02-18 Hetero Research Foundation Amide glycosides

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921116A1 (de) * 1997-12-04 1999-06-09 F. Hoffmann-La Roche Ag N-(4-carbamimido-phenyl)-glycinamidderivate
WO2000040548A1 (en) * 1999-01-02 2000-07-13 Aventis Pharma Deutschland Gmbh Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
EP1078917A1 (de) * 1998-02-17 2001-02-28 Ono Pharmaceutical Co., Ltd. Amidinoderivate und medikamente die diese als aktiven bestandteil enthalten
WO2001014320A1 (en) * 1999-08-23 2001-03-01 Morphochem Ag Compounds that inhibit tryptase activity
WO2001062717A1 (de) * 2000-02-23 2001-08-30 Merck Patent Gmbh Aminosulfonylbiphenylderivate
WO2001070678A2 (de) * 2000-03-24 2001-09-27 Merck Patent Gmbh Substituierte biphenylderivate
WO2002057236A1 (en) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenyl derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041402A1 (de) * 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921116A1 (de) * 1997-12-04 1999-06-09 F. Hoffmann-La Roche Ag N-(4-carbamimido-phenyl)-glycinamidderivate
EP1078917A1 (de) * 1998-02-17 2001-02-28 Ono Pharmaceutical Co., Ltd. Amidinoderivate und medikamente die diese als aktiven bestandteil enthalten
WO2000040548A1 (en) * 1999-01-02 2000-07-13 Aventis Pharma Deutschland Gmbh Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
WO2001014320A1 (en) * 1999-08-23 2001-03-01 Morphochem Ag Compounds that inhibit tryptase activity
WO2001062717A1 (de) * 2000-02-23 2001-08-30 Merck Patent Gmbh Aminosulfonylbiphenylderivate
WO2001070678A2 (de) * 2000-03-24 2001-09-27 Merck Patent Gmbh Substituierte biphenylderivate
WO2002057236A1 (en) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenyl derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUTZ WEBER ET AL.: "Optimierung der biologischen Aktivität von kombinatorischen Verbindungsbibliotheken durch einen genetischen Algorithmus", ANGEWANDTE CHEMIE., vol. 107, no. 20, 1995, VCH VERLAGSGESELLSCHAFT, WEINHEIM., DE, pages 2452 - 2454, XP002238358, ISSN: 0044-8249 *

Also Published As

Publication number Publication date
CA2473164A1 (en) 2003-08-07
WO2003064378A2 (de) 2003-08-07
ZA200405544B (en) 2005-07-13
EP1470104A2 (de) 2004-10-27
DE10204072A1 (de) 2003-08-14
US20060058389A1 (en) 2006-03-16
JP2005516062A (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
WO2001064643A3 (en) Benzamides and related inhibitors of factor xa
AU4327600A (en) Aryl sulfonyls as factor xa inhibitors
DE60112974D1 (en) Carbolinderivate
MY147780A (en) Carboxamide compounds and their use as calpain inhibitors
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
WO2005013914A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
WO2002046129A3 (en) Inhibitors of histone deacetylase
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
ZA200306419B (en) Phenyl derivatives.
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
DE60216233D1 (en) Carbolinderivate
MXPA03009750A (es) Compuestos quimicos.
WO2003065987A3 (en) Granzyme b inhibitors
AU2003228674A1 (en) Muscarinic antagonists
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
MXPA03010761A (es) Combinaciones farmaceuticas.
MXPA03002911A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003702590

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2473164

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003564002

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003702590

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2006058389

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10501931

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10501931

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003702590

Country of ref document: EP